Clinical Evaluation of Desoxymethasone - a new Corticosteroid.
In a double blind paired comparison study, the patients with steroid responsive dermatoses received desoxymethasone 0.25% on lesions on both sides of the body for first 4 days and desoxymethasone 0.25% on one side and 0.05% on the other side for the next 10 days. There was no significant difference in the percent reduction in severity scores of symptoms in global assessment or patient preference between the two treatments.